Restricted accessResearch articleFirst published online 2014-06
On the Application of Nafion Membrane for the Preparation of 90 Y Skin Patches,Quality Control,and Biological Evaluation for Treatment of Superficial Tumors
This article describes the preparation, quality control, and biological evaluation of 90Y-skin patches based on Nafion® membrane as a viable treatment modality for superficial skin tumors such as melanoma. To arrive at the conditions for optimum uptake of 90Y on the membrane, influence of various experimental parameters, such as pH of the feed solution, inactive yttrium carrier concentration, reaction volume, contact time, and temperature, was systematically investigated. Under the optimized conditions, >95% of the 90Y activity (37–185 MBq) could be incorporated in the Nafion membranes to prepare 90Y-skin patches. Quality control tests were carried out to ensure nonleachability, uniform distribution of activity, and stability of the 90Y-patches. Mice bearing transplanted melanoma tumors that were treated with two doses of 74 MBq 90Y-Nafion membrane sources showed complete tumor regression. Histopathological examination of the treated area showed absence of tumor. The results of the study indicate the potential of 90Y-Nafion membrane sources for treatment of superficial skin tumors.
Get full access to this article
View all access options for this article.
References
1.
LeiterU, GarbeC. Epidemiology of melanoma and nonmelanoma skin cancer—the role of sunlight. In: ReichrathJ (ed.), Sunlight, Vitamin D and Skin Cancer. In: Advances in Experimental Medicine & Biology, Vol. 62, Landes Bioscience and Springer Science+Business media, New York. 2008.
2.
ChummanS, Mc LeanNR. Management of malignant skin cancers. Surgery (Oxford), 2011; 29:529.
3.
GlosterHMJr., BrodlandDG. The epidemiology of skin cancer. Dermatol Surg, 1996; 22:217.
4.
GarbeC, PerisK, HauschildA, et al. Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer, 2010; 46:270.
5.
EisemannN, WeldmannA, GellerAC, et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol, 2014; 134:43.
6.
McGuireJF, GeNN, DysonS. Nonmelanoma skin cancer of the head and neck I: Histopathology and clinical behavior. Am J Otolaryngol, 2009; 30:121.
NevilleJA, WelchE, LeffellDJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol, 2007; 4:462.
9.
HaighPI, DiFronzoLA, McCreadyDR. Optimal excision margins for primary cutaneous melanoma: A systematic review and meta analysis. Can J Surg, 2003; 46:419.
10.
IyerS, FriedliA, BowesL, et al. Full face laser resurfacing therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Laser Surg Med, 2004; 34:114.
FischbachAJ, SauseWT, PlenkHP. Radiation therapy for skin cancer. West J Med, 1980; 133:379.
13.
VenessM, RichardsS. Role of modern radiotherapy in treating skin cancer. Australas J Dermatol, 2003; 44:159.
14.
GuixB, FinestresF, TelloJ, et al. Treatment of skin carcinomas of the face by high-dose-rate brachytherapy and custom-made surface molds. Int J Radiat Oncol Biol Phys, 2000; 47:95.
15.
LeeJD, ParkKK, LeeMG, et al. Radionuclide therapy of skin cancers and Bowen's disease using a specially designed skin patch. J Nucl Med, 1997; 38:697.
16.
ChungYL, LeeJD, BangD, et al. Treatment of Bowen's disease with a specially designed radioactive skin patch. Eur J Nucl Med, 2000; 27:842.
17.
MukherjeeA, PandeyU, SarmaHD, et al. Preparation and evaluation of 90Y skin patches for therapy of superficial tumours in mice. Nucl Med Commun, 2002; 23:243.
18.
SalgueiroMJ, DuranH, PalmieriM, et al. Bioevaluation of 32P patch designed for the treatment of skin diseases. Nucl Med Biol, 2008; 35:233.
19.
SaxenaSK, KumarY, DashA. Nafion-Zirconium phosphate composite membrane: A new approach to prepare 32P patches for superficial brachytherapy applications. Cancer Biother Radiopharm, 2012; 27:276.
20.
MukherjeeA, PandeyU, SarmaHD, et al. Bioevaluation of radioactive bandages in a murine model of melanoma. Int J Radiat Biol, 2003; 79:839.
21.
SaxenaSK, PandeyAK, TandonP, et al. A novel approach to prepare 90Y-EGMP patches for superficial brachytherapy. Appl Radiat Isot, 2009; 67:1416.
22.
GuptaP, GuptaS, MalhotraA, et al. Basal cell carcinoma treatment using Phosphorus-32 skin patches: A three year follow up study [abstr]. J Nucl Med, 2012; 53 (Suppl 1):62.
23.
SeddaAF, RossiG, CiprianiC, et al. Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma. Clin Exp Dermatol, 2008; 33:745.
24.
CarrazzoAM, CiprianiC, DonatiP, et al. Dermo beta brachytherapy with 188Re in extramammary Paget's disease. G Ital Dermatol Venereol, 2014; 149:115.
25.
ChakravartyR, DashA, PillaiMRA. Availability of yttrium-90 from strontium-90: A nuclear medicine perspective. Cancer Biother Radiopharm, 2012; 27:621.
26.
YuTL, LinHL, ShenKS, et al. Nafion/PTFE composite membranes for fuel cell applications. J Polym Res, 2004; 11:217.
27.
NasefMM, YahayaAH. Adsorption of some heavy metal ions from aqueous solutions on Nafion-117 membrane. Desalination, 2009; 249:677.
28.
ChakravartyR, PandeyU, ManolkarRB, et al. Development of an electrochemical 90Sr-90Y generator for separation of 90Y suitable for targeted therapy. Nucl Med Biol, 2008; 35:245.
29.
Testing and Classification of Sealed Radioactive Sources. AERB SS-3 (Rev-1), A publication of Atomic Energy Regulatory Board, Mumbai-400 094, India. 2001. Available at: http://www.aerb.gov.in/AERBPortal/pages/English/t/publications/CODESGUIDES/SS-03-REV1.PDF
30.
MerloA, HausmannO, WasnerM, et al. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y labeled DOTA-D-Phe1-Tyr3-octreotide (DOTATOC): A pilot study in human gliomas. Clin Cancer Res, 1999; 5:1025.
31.
KhanMK, KhanN, AlmasanA, et al. Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Onco Targets Ther, 2011; 4:137.
